|
|
|
- Bender N, Rangoonwala B, Rosenthal J & Vasmant D (1990) Clin Physiol & Biochem 8 (suppl 1) 44-52
- Lombard C (2000) University of Berne, 10th ESVIM Congress, Neuchatel, Sept 2000
- Dzau V J (1988) Am J Cardiol 62, 76E-81E
- Francis G (2000) Cleveland Clinic Foundation, 10th ESVIM Congress, Sept 2000
- McDonald K M, Mock J, Daloia A, Parrish T, Hauer K, Francis G, Stillman A & Cohn J N (1995) Circulation 91, 2043-2048
- Staeter-Knowlen I M, Dell'Italia L J, Dai J, Hankes G H, Dillon A R, Cartee R E, Pohost G M & Ku D D (1999) Am J Physiol 277, H1924-1930
- Omosu M (1992) Japanese J Nephrol 34, 883-894
- Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342, 145-153 & 201-202
- Sent U, Haarer Kindler M, Zschiesche E, Huttig A, Skrodzki M, Schille F & Trautvetter E (2000) Kleintierpraxis 45, 123-131
- Zhang X, Xie Y W, Nasjletti A, Xu X, Wolin M S, Hintze T H (1997) Circulation 95, 176-182
Vasotop is indicated for the treatment of heart failure in dogs and has been shown to improve the related symptoms and prognosis. Vasotop 1.25, Vasotop 2.5 and Vasotop 5 contain 1.25mg, 2.5mg and 5mg ramipril Ph. Eur. as the active ingredient, respectively. For contra-indications and warnings see datasheet. Further information is available on request. Legal category POM ® registered trademark. Intervet UK Limited, Walton Manor, Milton Keynes MK7 7AJ.
|